People

William T. Golden, a corporate executive and a longtime advocate of progress in science and technology, was named chairman of the board of trustees of the American Museum of Natural History last month. The 79-year-old Golden, who serves in an advisory capacity at several corporations, including General American. Investors Co. and Block Drug Co., says his aim is to provide "leadership without domination" in representing the board to the museum's president. The new chairman has been a museum trust

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Investors Co. and Block Drug Co., says his aim is to provide "leadership without domination" in representing the board to the museum's president. The new chairman has been a museum trustee since 1968 and most recently served as vice-chairman. He recalls that his lifelong love affair with science began when he received his first radio and transmitting device at the age of 13.

The board is currently developing plans for the modernization of the New York City museum, a 5 to 10 year program that will provide for renovations of museum exhibitions and structures as well as support for the activities of the museum's scientists.

Since its founding in 1869, the museum has become the largest natural-history museum in the world, supporting extensive research in the zoologic, anthropologic, and earth sciences. Golden sees this research as crucial for the future of the museum, predicting that basic research will grow in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies